JP2011511011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011511011A5 JP2011511011A5 JP2010545285A JP2010545285A JP2011511011A5 JP 2011511011 A5 JP2011511011 A5 JP 2011511011A5 JP 2010545285 A JP2010545285 A JP 2010545285A JP 2010545285 A JP2010545285 A JP 2010545285A JP 2011511011 A5 JP2011511011 A5 JP 2011511011A5
- Authority
- JP
- Japan
- Prior art keywords
- ethynyl
- androstane
- diol
- crystalline
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005546 17α-ethynyl-3α-androstanediol Drugs 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 29
- 238000001757 thermogravimetry curve Methods 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 230000004580 weight loss Effects 0.000 claims description 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 150000008064 anhydrides Chemical class 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 12
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 8
- 238000001228 spectrum Methods 0.000 claims description 8
- 238000001069 Raman spectroscopy Methods 0.000 claims description 6
- 238000002844 melting Methods 0.000 claims description 6
- 230000008018 melting Effects 0.000 claims description 6
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 238000004455 differential thermal analysis Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000013078 crystal Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000007858 starting material Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000002411 thermogravimetry Methods 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 2
- 206010008263 Cervical dysplasia Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 238000002441 X-ray diffraction Methods 0.000 claims description 2
- 239000007894 caplet Substances 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 2
- 229940068968 polysorbate 80 Drugs 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 2
- 238000004442 gravimetric analysis Methods 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2647208P | 2008-02-05 | 2008-02-05 | |
| US9369408P | 2008-09-02 | 2008-09-02 | |
| PCT/US2009/033280 WO2009100258A1 (en) | 2008-02-05 | 2009-02-05 | Pharmaceutical solid state forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011511011A JP2011511011A (ja) | 2011-04-07 |
| JP2011511011A5 true JP2011511011A5 (enExample) | 2012-06-21 |
Family
ID=40952461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010545285A Pending JP2011511011A (ja) | 2008-02-05 | 2009-02-05 | 医薬的固体状態形態 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8518922B2 (enExample) |
| EP (1) | EP2249838A4 (enExample) |
| JP (1) | JP2011511011A (enExample) |
| KR (1) | KR20100113602A (enExample) |
| CN (2) | CN101939009B (enExample) |
| AU (1) | AU2009212314C1 (enExample) |
| CA (1) | CA2712005C (enExample) |
| EA (1) | EA018974B9 (enExample) |
| IL (1) | IL207378A0 (enExample) |
| WO (1) | WO2009100258A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103626744B (zh) | 2007-12-07 | 2016-05-11 | 沃泰克斯药物股份有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的固体形式 |
| DK2273994T3 (en) * | 2008-04-03 | 2016-02-01 | Neurmedix Inc | PHARMACEUTICAL FORMS OF A MEDICINE |
| WO2011066582A1 (en) * | 2009-11-30 | 2011-06-03 | Harbor Biosciences, Inc. | Anticancer compounds and screening method |
| US20140148348A1 (en) | 2010-01-13 | 2014-05-29 | Christine Kuslich | Dectection of gastrointestinal disorders |
| CN103237901B (zh) | 2010-03-01 | 2016-08-03 | 卡里斯生命科学瑞士控股有限责任公司 | 用于治疗诊断的生物标志物 |
| CA2795776A1 (en) | 2010-04-06 | 2011-10-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers for disease |
| US20120220560A1 (en) * | 2010-12-17 | 2012-08-30 | White Steven K | Steroid tetrol solid state forms |
| CN104173353B (zh) * | 2013-05-22 | 2018-08-21 | 中国医药工业研究总院 | 不含表面活性剂的固体制剂及其制备方法 |
| HRP20210516T2 (hr) * | 2013-11-12 | 2021-10-01 | Vertex Pharmaceuticals Incorporated | Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr |
| CN105434444B (zh) * | 2014-09-29 | 2021-02-05 | 上海奥奇医药科技有限公司 | 一种A-失碳-5α雄甾烷化合物的口服制剂 |
| CA2966753A1 (en) | 2014-11-17 | 2016-05-26 | Arno Therapeutics, Inc. | Onapristone extended-release compositions and methods |
| AU2016326657B2 (en) | 2015-09-25 | 2019-10-24 | Context Biopharma, Inc. | Methods of making onapristone intermediates |
| CA3008422A1 (en) | 2015-12-15 | 2017-06-22 | Context Biopharma Inc. | Amorphous onapristone compositions and methods of making the same |
| US20180148471A1 (en) | 2016-11-30 | 2018-05-31 | Arno Therapeutics, Inc. | Methods for onapristone synthesis dehydration and deprotection |
| AU2018246257B2 (en) * | 2017-03-30 | 2022-05-12 | Merck Patent Gmbh | Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol |
| RU2668526C1 (ru) * | 2017-08-18 | 2018-10-01 | Федеральное государственное бюджетное учреждение "Информационно-методический центр по экспертизе, учету и анализу обращения средств медицинского применения" Федеральной службы по надзору в сфере здравоохранения | Способ идентификации и последующего количественного определения основных компонентов в инъекционных лекарственных средствах |
| IL311084A (en) | 2018-11-30 | 2024-04-01 | Caris Mpi Inc | New generation molecular characterization |
| CN111773388B (zh) * | 2019-04-04 | 2023-07-18 | 上海奥奇医药科技有限公司 | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 |
| WO2021112918A1 (en) | 2019-12-02 | 2021-06-10 | Caris Mpi, Inc. | Pan-cancer platinum response predictor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE681869C (de) * | 1935-11-22 | 1939-10-03 | Schering Ag | Verfahren zur Darstellung von tertiaeren Alkoholen der Cyclopentanopolyhydrophenanthrenreihe |
| CH202847A (de) | 1937-06-26 | 1939-02-15 | Chem Ind Basel | Verfahren zur Darstellung von Acetylen-Derivaten der Cyclopentanopolyhydrophenanthren-Reihe. |
| JP3179495B2 (ja) | 1992-08-28 | 2001-06-25 | ボーン ケア インターナショナル インコーポレイテッド | １α，２４（Ｓ）−ジヒドロキシビタミンＤ▲下２▼の調製及び使用方法 |
| US5567830A (en) * | 1994-02-14 | 1996-10-22 | Cocensys, Inc. | Process for synthesis of acetylenic carbinols |
| WO1997036893A1 (en) | 1996-03-29 | 1997-10-09 | Duphar International Research B.V. | Piperazine and piperidine compounds |
| ZA986614B (en) | 1997-07-25 | 1999-01-27 | Gilead Sciences | Nucleotide analog composition |
| US7045513B1 (en) | 1999-03-18 | 2006-05-16 | Genelabs Technologies, Inc. | DHEA composition and method |
| EP1228083A2 (en) | 1999-09-30 | 2002-08-07 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatment of androgen receptor driven conditions |
| US6777399B2 (en) * | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| SK288222B6 (sk) | 2000-12-14 | 2014-09-04 | Ortho-Mcneil Pharmaceutical, Inc. | Steroidné hormonálne prípravky a spôsoby ich prípravy |
| AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
| DE10314610A1 (de) | 2003-04-01 | 2004-11-04 | Aventis Pharma Deutschland Gmbh | Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung |
| US7540016B2 (en) * | 2004-07-21 | 2009-05-26 | Beachhead Solutions, Inc. | System and method for lost data destruction of electronic data stored on a portable electronic device which communicates with servers that are inside of and outside of a firewall |
| US7964604B2 (en) | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
| TW200730505A (en) * | 2005-12-07 | 2007-08-16 | Merck & Co Inc | Polymorphs of an androgen receptor modulator |
| TWI305979B (en) * | 2006-03-24 | 2009-02-01 | Hon Hai Prec Ind Co Ltd | Wireless transceiving system |
| EP2486924B1 (en) * | 2006-04-22 | 2018-12-26 | Neurmedix, Inc. | Drugs and uses |
| DE102007054497B3 (de) | 2007-11-13 | 2009-07-23 | Sanofi-Aventis Deutschland Gmbh | Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung |
-
2009
- 2009-02-05 CN CN200980104255XA patent/CN101939009B/zh not_active Expired - Fee Related
- 2009-02-05 EP EP09709386A patent/EP2249838A4/en not_active Withdrawn
- 2009-02-05 CA CA2712005A patent/CA2712005C/en not_active Expired - Fee Related
- 2009-02-05 EA EA201070713A patent/EA018974B9/ru not_active IP Right Cessation
- 2009-02-05 KR KR1020107019161A patent/KR20100113602A/ko not_active Ceased
- 2009-02-05 CN CN2013102558234A patent/CN103467554A/zh active Pending
- 2009-02-05 JP JP2010545285A patent/JP2011511011A/ja active Pending
- 2009-02-05 WO PCT/US2009/033280 patent/WO2009100258A1/en not_active Ceased
- 2009-02-05 AU AU2009212314A patent/AU2009212314C1/en not_active Ceased
- 2009-02-12 US US12/370,510 patent/US8518922B2/en active Active
-
2010
- 2010-08-03 IL IL207378A patent/IL207378A0/en unknown
-
2013
- 2013-06-17 US US13/919,593 patent/US9314471B2/en active Active - Reinstated
- 2013-06-17 US US13/919,386 patent/US20130345184A1/en not_active Abandoned
- 2013-06-17 US US13/919,728 patent/US20130338125A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011511011A5 (enExample) | ||
| JP2022058395A5 (enExample) | ||
| CA2939546C (en) | Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use | |
| KR102322802B1 (ko) | Rad1901-2hcl의 다형 형태 | |
| CN102510855B (zh) | N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形 | |
| TWI303634B (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,4']bipyridinyl in pure crystalline form, process for synthesis, and pharmaceutical composition containing the same | |
| KR20100113602A (ko) | 고체 형태의 약제 | |
| Park et al. | Use of CP/MAS solid-state NMR for the characterization of solvate molecules within estradiol crystal forms | |
| JP2021529783A (ja) | Ｒａｄ１９０１−２ｈｃｌの多形形態 | |
| AU2023201010B2 (en) | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide | |
| RU2006132352A (ru) | Кристаллическая полиморфная форма базедоксифен ацетата | |
| Zhou et al. | Synthesis, crystal structures and phase transformation of the new solid-state forms of tetrandrine | |
| JP7784424B2 (ja) | テガビビントの結晶形態、調製方法、及びその使用 | |
| Variankaval et al. | Characterization of crystal forms of β-estradiol–thermal analysis, Raman microscopy, X-ray analysis and solid-state NMR | |
| US12011442B2 (en) | Solid-state forms of Abemaciclib, their use and preparation | |
| JP2010111702A (ja) | 複素環化合物、その製造法および用途 | |
| WO2015113370A1 (zh) | 一种甜菊糖a苷晶体及其制备方法和用途 | |
| WO2012055163A1 (zh) | 来曲唑i型结晶及其制备方法 | |
| CN102229558A (zh) | 西洛多辛的新晶型δ、它的制备方法和包含它的药物组合物 | |
| JP2022540466A (ja) | 非晶質ウムブラリシブモノトシレート | |
| WO2020225782A1 (ko) | 무정형의 pi3k 저해제 및 이를 포함하는 약학적 조성물 | |
| TWI905090B (zh) | Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物 | |
| RU2802964C2 (ru) | Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида | |
| HK40100623A (zh) | [1，2，4]三唑[4，3-b]哒嗪化合物的晶型及其制备方法和应用 | |
| HK40100623B (zh) | [1，2，4]三唑[4，3-b]哒嗪化合物的晶型及其制备方法和应用 |